Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2017³â Á¦32Â÷ Workshop °³ÃÖ ¾È³»
"The next wave of biopharmaceutical R&D for 4th industrial revolution"
2017³â 10¿ù 19ÀÏ(¸ñ) ~ 10¿ù 20ÀÏ (±Ý) / Á¦ÁÖ Èִнº¾ÆÀÏ·£µå
1. ±Í»çÀÇ ¹«±ÃÇÑ ¹ßÀü°ú ±ÍÇÏÀÇ °Ç½ÂÇϽÉÀ» ±â¿øÇÕ´Ï´Ù.
2. Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸¿¡¼´Â Á¦32Â÷ ¿öÅ©¼¥À» "The next wave of biopharmaceutical R&D for 4th industrial revolution" À̶ó´Â ÁÖÁ¦·Î ´ÙÀ½°ú °°ÀÌ °³ÃÖÇÏ¿À´Ï, ȸ¿ø ¿©·¯ºÐÀÇ ¸¹Àº Âü¿© ¹Ù¶ø´Ï´Ù.
¡á Çà»ç°³¿ä
Çà»ç¸í
|
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2017³â Á¦32Â÷ Workshop
|
ÁÖÁ¦
|
"The next wave of biopharmaceutical R&D for 4th industrial revolution"
|
ÀϽÃ
|
2017³â 10¿ù 19ÀÏ(¸ñ) 13:00 ~ 10¿ù 20ÀÏ(±Ý) 15:00
|
Àå¼Ò
|
Á¦ÁÖ Èִнº ¾ÆÀÏ·£µå
(ÁÖ¼Ò : Á¦ÁÖÆ¯º°ÀÚÄ¡µµ ¼±ÍÆ÷½Ã ¼º»êÀ¾ °í¼º¸® 182¹øÁö)
|
»çÀüµî·Ï±â°£
|
2017³â 8¿ù 21ÀÏ (¿ù) ~ 10¿ù 11ÀÏ (¼ö)
1) ȨÆäÀÌÁö (www.nonclinical.or.kr)³» Á¦32Â÷ ¿öÅ©¼¥ »çÀüµî·Ï ¸Þ´º ÀÌ¿ë
2) ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ µî·Ï °¡´É
|
µî·Ïºñ
|
»çÀüµî·Ï 15¸¸¿ø(Çлý 10¸¸¿ø), ÇöÀåµî·Ï 15¸¸¿ø(¼÷¹Ú Á¦°ø ºÒ°¡), Ä«µå°áÁ¦ ºÒ°¡ÇÔ.
1) ÀÚ·áÁý, ¼ö·áÁõ, ¼÷¹Ú (4 or 5ÀÎ/1½Ç), ½Äºñ Æ÷ÇÔ
2) ¼¼±Ý°è»ê¼ ¹ß±Þ (ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇϽŠºÐÀº »ç¾÷ÀÚµî·ÏÁõ ÷ºÎ ¿ä¸Á
3) ÇöÀåµî·Ï ¹× Çлýµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ
4) ÀԱݰèÁÂ: ¿ì¸®ÀºÇà 1005-101-920320 ¢ßÅ¥º£½ºÆ®ÄÁ¼³ÆÃ ºñÀӻ󿬱¸È¸
5) ÀԱݸ¶°¨: 2017³â 10¿ù 11ÀÏ (¼ö), ÀÔ±Ý ½Ã ¼Ò¼Ó, ¼º¸í ±âÀÔ ¿ä¸Á
|
¹®ÀÇ
|
±âŸ ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
KSNS »ç¹«±¹ : Tel. 031-706-2995 / E-mail. ksns@nonclinical.or.kr / ´ã´çÀÚ. °íÁ¾È
|
°ø¹® ´Ù¿î·Îµå
|
°ø¹® - Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ Á¦32Â÷ ¿öÅ©¼¥ ÇÁ·Î±×·¥ ¾È³»
|
¡á µî·Ï¾È³»
- »çÀüµî·Ï ¾È³»
µî·Ï±â°£
|
2017³â 8¿ù 18ÀÏ (±Ý) 09½Ã ~ 10¿ù 11ÀÏ (¼ö) 18½Ã
(Âü°í)
10¿ù 19ÀÏ (¸ñ) µî·Ï½ÃÀÛ ½Ã°¢ : ¿ÀÈÄ 12½Ã
10¿ù 20ÀÏ (±Ý) Àüü ÇÁ·Î±×·¥ ¸¶Ä¡´Â ½Ã°¢ : ¿ÀÈÄ 15½Ã
|
µî·Ï¹æ¹ý
|
- ¿¬±¸È¸ ȨÆäÀÌÁö (www.nonclinical.or.kr) ÇмúÇà»ç >»çÀüµî·Ï ¸Þ´º ÀÌ¿ë
- ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ, »çÀüµî·ÏÀÌ °¡´ÉÇÕ´Ï´Ù.
|
- µî·Ïºñ < Áß¿ä°øÁö >ÇöÀåµî·ÏÀº ¼÷¼Ò°¡ Á¦°ø µÇÁö ¾Ê½À´Ï´Ù.
µî·Ïºñ ±¸ºÐ
|
»çÀüµî·Ï
|
ÇöÀåµî·Ï
|
Á¤È¸¿ø
|
150,000¿ø
|
150,000¿ø (¼÷¼ÒÁ¦°ø ¾øÀ½)
|
Çлýȸ¿ø
|
100,000¿ø
|
100,000¿ø (¼÷¼ÒÁ¦°ø ¾øÀ½)
|
- »çÀüµî·Ïºñ : ÀÚ·áÁý, ¼ö·áÁõ, ½Äºñ, ¼÷¹Úºñ Æ÷ÇÔ
- ¼¼±Ý°è»ê¼ ¹ß±Þ(ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇÒ °æ¿ì, ¿Â¶óÀÎ µî·Ï¶§ ¼¼±Ý°è»ê¼ ¹ßÇàÇà¿©ºÎ¸¦ üũÇϰí, »ç¾÷ÀÚµî·ÏÁõ »çº»À» ¹Ýµå½Ã ÷ºÎ
- ÇöÀåµî·Ï ¹× Çлýµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ
|
- ¹«ÅëÀåÀÔ±Ý (°èÁÂÀÌü)
ÀԱݰèÁÂ
|
- ¿ì¸®ÀºÇà 1005-101-920320 ¢ß Å¥º£½ºÆ®ÄÁ¼³ÆÃ ºñÀӻ󿬱¸È¸
|
ÀԱݸ¶°¨
|
- ~ 2017³â 10¿ù 11ÀÏ (¼ö) 18½Ã ±îÁö
|
- ÀԱݽà ¹Ýµå½Ã "¼Ò¼Ó/¼º¸í" À» ±âÀÔÇϼ¼¿ä.
- ¹«ÅëÀå ÀÔ±Ý(°èÁÂÀÌü)ÀÌü ÈÄ, »ç¹«±¹¿¡¼ ÀÔ±ÝÀ» È®ÀÎÇÏ´Â ½Ã°£ÀÌ ÇÊ¿ä ÇÕ´Ï´Ù.
- ½Å¿ëÄ«µå °áÁ¦´Â ºÒ°¡´É ÇÕ´Ï´Ù.
- ±âŸ µî·Ï °ü·Ã ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
TEL. 031-706-2995, E-mail. ksns@nonclinical.or.kr, °íÁ¾È
|
¡á ÇÁ·Î±×·¥ ¾È³»
- ÀϽÃ: 2017³â 10¿ù 19ÀÏ(¸ñ) ~ 10¿ù 20ÀÏ(±Ý)
- Àå¼Ò: Á¦ÁÖ Èִнº ¾ÆÀÏ·£µå(Á¦ÁÖÆ¯º°ÀÚÄ¡µµ ¼±ÍÆ÷½Ã ¼º»êÀ¾ °í¼º¸® 182¹øÁö)
- ÁÖÁ¦: The next wave of biopharmaceutical R&D for 4th industrial revolution
|
Day 1 |
10¿ù 19ÀÏ (¸ñ) |
12:00 ~ 13:00 |
µî·Ï |
13:00 ~ 13:10 |
°³È¸»ç (ÀÌ»óÈ£ ȸÀå) |
Session 1 |
13:10 ~ 13:50 |
¹ÙÀÌ¿À»ê¾÷ »ýŰè Ȱ¼ºÀ» À§ÇÑ Á¤Ã¥ Á¦¾È°ú 18³âµµ ¹ÙÀÌ¿À R&D ÁßÁ¡ ÃßÁø ±âȹ ¹æÇâ (KEIT ¹ÙÀÌ¿À∙ÀǾàPD ÀÌ»óÈ£) |
13:50 ~ 14:30 |
Á¤¹ÐÀÇÇÐ ÆÐ·¯´ÙÀÓ º¯È¼Ó¿¡ À¯Àüü ºòµ¥ÀÌÅÍ ¹× AI Ȱ¿ë ½Å¾à°³¹ß Àü·« (½ÅÅ×Ä«¹ÙÀÌ¿À, ±èżø) |
14:30 ~ 15:20 |
Booth exhibition & Coffee Break |
Session 2 |
15:20 ~ 16:00 |
Artificial applicable intelligence in drug discovery is to be experimentally verifiable
(½ºÅÄ´ÙÀÓ, ±èÁøÇÑ) |
16:00 ~ 16:40 |
Development of alternative toxicity testing models for nonclinical cardiotoxicity test (KIT, ±è±â¼®) |
16:40-17:00 |
Coffee Break |
Session 3 |
17:00 ~17:40 |
Development of 3D multi-layer based organ on a chip platform (Á¦ÁÖ´ë, ÃÖ°æÇö) |
17:40 ~ 18:20 |
Strategic Non-Clinical Evaluation for Drug Development: T2B Infrastructure
(¼¿ï¾Æ»êº´¿ø, ÃÖÀº°æ) |
18:30 ~ 20:00 |
Dinner & Social networking |
Day 2 |
10¿ù 20ÀÏ (±Ý) |
07:00 ~ 09:00 |
¾ÆÄ§ ½Ä»ç |
ºÐ°ú¹ßÇ¥ |
µ¶¼ººÐ°ú |
¾àµ¿·ÂÇкаú |
¾àÈ¿¾à¸®ºÐ°ú |
Çѱ¹»ê¾÷±â¼úÆò°¡°ü¸®¿ø ¼º°ú¹ßǥȸ |
09:00 ~ 09:40 |
Human microbiota-associated minipig as a nonclinical model for metabolic disorders
(¼¿ï´ë, ¹ÚÁßÈÆ) |
Flow Cytometry: A powerful tool to investigate immune disorders in Preclinical and Clinical Development (Envigo, Paula Mendosa) |
Ocular Gene and Cell Therapy Safety Studies
(MPI, Josh Bartoe) |
¹æ»ç¼±µ¿À§¿ø¼Ò Ç¥Áö¹°Áú ±â¹Ý ADME Æò°¡½Ã½ºÅÛ °³¹ß
(Çѱ¹¿øÀÚ·ÂÀÇÇпø) |
09:40 ~ 10:20 |
NOAEL(No Observed Adverse Effect Level)ÀÇ ÀÌÇØ
(KIT, À̺´¼®) |
Regulation of drug transporters and enzymes by the vitamin D receptor and its pharmacokinetic impact
(°¡Ãµ´ë, ¸ÍÇÑÁÖ) |
Á¦ÁÖ»ê Èæ¹« ÃßÃâ¹°ÀÇ NAFLD °³¼±È¿°ú
(Á¦ÁÖÅ×Å©³ëÆÄÅ©, ±è±â¿Á) |
Ç÷°üÈµÈ 3Â÷¿ø »ýüÁ¶Á÷(°£/½ÉÀå, ¾Ï) ¸ð»ç Ĩ ±â¹Ý ¾à¹° È¿´É µ¶¼º Æò°¡ ½Ã½ºÅÛ °³¹ß (Çѱ¹°úÇбâ¼ú¿¬±¸¿ø) |
10:20 ~ 10:40 |
Booth exhibition & Coffee Break |
10:40 ~ 11:20 |
Immunotoxicology in preclinical and clinical studies of antibody based therapeutics
(CRL, Norbert Makori) |
Prediction of complex drug-drug Interactions (DDIs) using physiologically based pharmacokinetic (PBPK) models with in vitro inhibition data
(CJÇコÄɾî, ±è¼öÁø) |
Nonclinical study of Best-in-Class Uricosuric Agent for Hyperuricemia & Gout
(JWÁß¿ÜÁ¦¾à, Â÷ÁÖ¿µ) |
Á¦ºê¶óÇǽ¬ ±â¹Ý À¯È¿¼º ¾ÈÀü¼º ¾à¹°¼º Æò°¡¼ºñ½º
(Çѱ¹ÈÇבּ¸¿ø) |
11:20 ~ 12:00 |
ÀǾàǰÀÇ È¯°æÀ§ÇؼºÆò°¡ - Environmental risk assessment of medicinal products (LGÈÇÐ, Á¤Àº¼ö) |
¾àµ¿·ÂÇаú ½Å¾à°³¹ß
(µ¿¾ÆST, ½ÉÇöÁÖ) |
Metabolic Reprogramming By PKCK2
(¿¬¼¼´ë, ¾ç°æ¹Ì) |
½Å¾à ½ÇÆÐÀ² °¨¼Ò¸¦ À§ÇÑ »çÀü ¿¹Ãø Æò°¡ Ç÷§Æû ±¸Ãà ¹× ¼ºñ½º
(¼¿ï¾Æ»êº´¿ø) |
12:00 ~ 13:30 |
Luncheon seminar & Booth exhibition |
Session 4 |
13:30 ~ 14:10 |
´ë»ç¼ºÁúȯ Çõ½Å½Å¾à Ÿ°Ù ¹ß±¼ Ç÷§Æû ¹× ½Å¾à°³¹ß Àü·«
(°¡Ãµ´ë, ÃÖö¼ö) |
14:10 ~ 14:50 |
NexMab¢â-Based Antibody-Drug Conjugate for the Treatment of Breast/Gastric Cancer
(¾ËÅ׿ÀÁ¨, À̼±¹è) |
14:50 ~ 15:00 |
Æóȸ»ç (¿À¼¼¿õ ºÎȸÀå) & °æÇ° Ãß÷ |
¡Ø »ó±â ÇÁ·Î±×·¥Àº ¿¬ÀÚ ¹× ±âŸ »çÁ¤À¸·Î º¯µ¿ ¼ö ÀÖ½À´Ï´Ù.
¡á Á¦ÁÖ Èִнº¾ÆÀÏ·£µå ã¾Æ¿À½Ã´Â ±æ
|